Press Release

Net.Orange Inc. and the Mary Crowley Cancer Research Centers announce expansion of strategic collaboration

Dallas, TX (Feb. 27, 2008) – The Mary Crowley Cancer Research Centers (MCCRC) today announced an expansion of its strategic collaboration with Texas-based Net.Orange Inc., inventor of the revolutionary cOS™ (Clinical Operating System) and many general and therapeutic-specific technology solutions.

For the past year, MCCRC’s site management organization has been using the Net.Orange cOS™ solution for clinical trial management to administer over 100 cancer clinical trials across a national network of 10 cancer centers. Using the cOS™, MCCRC connects disparate systems including eResearch, a clinical trial management system developed by Velos Inc., a partner of Net.Orange, and provides critical information access to internal and external roles in the clinical trials process.

With the expansion in the agreement, MCCRC will now deploy Net.Orange's specialized cancer treatment planning system, cOS™ TheraSystem, to provide oncologists and nurses with visibility and clinical decision support tools to manage a cancer patient's treatment plan. This new system will allow cancer care teams to implement traditional treatment regimens such as chemotherapy while at the same time, intelligently seek non-traditional alternatives, such as personalized molecular medicine and clinical trials, and identify the best available therapeutic approach for each patient.

David Shanahan, President of the Mary Crowley Cancer Research Centers commented, "We are very excited about our strategic relationship with Net.Orange. The cOS™ will provide much needed decision support tools to help our oncologists and their nursing staff to manage the ever increasing complexity of delivering care to cancer patients. By integrating the patient record with matching clinical trial protocols and standard of care protocols in a single environment will truly provide a meaningful view to the care team."

Dr. Vasu Rangadass, CEO, Net.Orange added, "We are excited to have the opportunity to interact with one of the most innovative oncology programs in the industry and address a significant unmet need. Cancer centers around the country have invested significant money in purchasing systems for billing, practice management, labs, radiology and medical records. cOS™ TheraSystem will allow these organizations to unlock the knowledge contained in these existing systems, while opening doors to relevant public information, and help them institute consistent decision making processes that are both clinically and financially optimal."

About the Mary Crowley Cancer Research Centers

Exploring investigational vaccine, gene, and cellular therapies with the goal of expanding treatment options for all cancer patients is the primary mission of the Mary Crowley Cancer Research Centers (MCCRC). MCCRC has performed hundreds of Phase I and Phase II clinical trial protocols, treated more than 3,000 patients, explored more than 100 new agents, and accomplished more than 140 FDA-approved clinical trials. The 501(c)(3) organization was established in 1992, is headquartered in Dallas and coordinates ten affiliate facilities nationwide. For more information, visit www.marycrowley.org

About Net.Orange, Inc.

Net.Orange™ simplifies an increasingly complex healthcare system through robust solutions that are designed to be visually-intuitive, rapidly deployed, and managed with ease. Net.Orange's innovative cOS™ (Clinical Operating System) solutions empower all constituents of the healthcare industry by leveraging an extraordinary suite of web-based applications and connectors to existing systems. The company is committed to the objective of helping customers provide superior quality patient care through better decision making and improved productivity. Net.Orange is headquartered in Irving, Texas. For more information, visit www.ndorange.com

# # #

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.